Tandem Diabetes Care (Nasdaq:TNDM) shares got a boost after hours today on third-quarter results that came in ahead of the consensus forecast.
Shares of TNDM rose nearly 20% to $15.89 apiece in post-market trading today.
The San Diego-based automated insulin delivery technology developer reported losses of $21.2 million. That equals 31¢ per share on sales of $249.3 million for the three months ended Sept. 30, 2025.
Tandem — one of the largest diabetes tech companies in the world — recorded a 9% bottom-line gain on a sales increase of 2.2%. The company said its third-quarter sales marked records for both the U.S. and internationally.
Losses per share landed 3¢ ahead of expectations on Wall Street. Sales also topped estimates as experts projected $235.8 million in revenue.
Highlights in the quarter included FDA clearance for an extended-wear infusion set, approval to deliver Lyumjev ultra-rapid acting insulin with its t:slim X2 pump and study findings highlighting the benefits of its automated insulin delivery system.
Additionally, although not during the quarter, the company recently announced that it launched its t:slim X2 insulin pump with the Abbott FreeStyle Libre 3 Plus CGM, adding a new sensor pairing to its offerings.
The company said it also progressed its multi-channel initiative by increasing pharmacy benefit coverage for its Tandem Mobi miniature durable pump to more than 40% of U.S. lives. It also introduced t:slim X2 supplies through a pharmacy benefit.
Tandem reaffirmed its full-year guidance for approximately $1 billion in revenue.
“Tandem delivered a strong third quarter performance marked by record quarterly sales, significant gross margin improvement, and meaningful progress on our key strategic initiatives,” said John Sheridan, president and CEO. “We are beginning to see the positive impact of our business transformation, which strengthens our ability to achieve Tandem’s near- and longer-term goals, while continuing our commitment to improve the lives of people with diabetes.”
